beyond glp-1 22% Weight Loss. Alone. How Is That Even Possible? GLP-1 Beyond Glucose - The

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA, has recently been licensed, and retatrutidea triple GIP/GLP-1/glucagon receptor agonistshows promising weight loss effects in ongoing phase 3 trials

Cleve Clin

At its peak, Novo controlled more than half of the global GLP-1 market

Food Quality vs Calories: What Matters More for Weight Loss and Metabolism

In Pennsylvania, a $3.5 billion facility in Fogelsville, announced in January 2026 and beginning construction in 2026, will manufacture tirzepatide and next-generation peptides including retatrutide, with completion expected in 2031

This is thought to be driven by reduced gallbladder motility and altered bile composition during periods of caloric restriction